In a groundbreaking move, the Alzheimer’s Association recommends blood tests for diagnosing cognitive impairment, potentially increasing access to treatment. This could revolutionize how Alzheimer's is diagnosed, especially in rural areas.
U.S. health officials are sounding the alarm about 7-hydroxymitragynine, an opioid ingredient found in energy drinks and gummies. A nationwide ban is being recommended to protect consumers from its dangers.
In a surprising turn of events, the FDA has allowed Sarepta Therapeutics to resume shipments of its gene therapy, Elevidys, for younger Duchenne muscular dystrophy patients who can walk, despite concerns over previous fatalities.
Doctors are pushing the FDA to remove black box warnings on low-dose estrogen treatments, arguing it discourages women from beneficial hormone therapies for menopause. Experts claim the risks are overstated and can hinder treatment.
As gene therapy for Duchenne muscular dystrophy faces scrutiny after tragic deaths, families like the Revells navigate the uncertain waters of hope and risk, questioning the future of their loved ones.
Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy is on hold due to safety issues. An FDA official warns the path to market approval is fraught with challenges, especially after patient deaths linked to liver injuries.
A 61-year-old man tragically died after being pulled into an MRI machine while wearing a large metallic chain. The incident highlights critical safety hazards associated with MRI scans and the importance of screening.
In a stunning move, the FDA has put clinical trials for Sarepta's gene therapy on hold due to alarming safety concerns after multiple patient deaths linked to acute liver failure. The company faces scrutiny as it navigates the fallout.
A recent NACCHO report reveals alarming staff shortages in local health departments, raising concerns about the public health safety net. As many as 19% report job losses, with funding cuts looming. Discover the implications for your community.
A new Covid variant, NB.1.8.1, raises alarms for its potential to spread rapidly and evade antibodies. Meanwhile, the FDA approves a long-lasting HIV injection, and concerns about public safety arise with ICE's rule changes.
